Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: A systematic review

Reproductive Biology and Endocrinology

Volumn 12, Issue 1, 2014, Pages

  Peigné, Maëliss ^a   Decanter, Christine ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

AMH; Cancer; Chemotherapy; Fertility preservation; Follicles; MIS; Ovarian toxicity

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; MUELLERIAN INHIBITING FACTOR; TAXANE DERIVATIVE;

BREAST CANCER; CANCER CHEMOTHERAPY; FEMALE; FERTILITY PRESERVATION; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; INFERTILITY THERAPY; LYMPHOMA; OVARIAN RESERVE; OVARY FOLLICLE; PREDICTION; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; FEMALE; HUMANS; OVARIAN FOLLICLE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899122803     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-12-26     Document Type: Review

References (60)

1. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996, 14:1718-1729.
2. Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM. Fertility after treatment for Hodgkin's disease. Ann Oncol 2002, 13(Suppl 1):138-147. 10.1093/annonc/13.S1.138, 12078896.
3. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001, 7:535-543. 10.1093/humupd/7.6.535, 11727861.
4. Reichman BS, Green KB. Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects. J Natl Cancer Inst Monogr 1994, 16:125-129.
5. Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Hum Reprod 1993, 8:2080-2087.
6. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000, 169:123-131. 10.1016/S0303-7207(00)00365-8, 11155944.
7. Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N. How do chemotherapeutic agents damage the ovary?. Hum Reprod Update 2012, 18:525-535. 10.1093/humupd/dms022, 22647504.
8. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007, 67:10159-10162. 10.1158/0008-5472.CAN-07-2042, 17974956.
9. Perez GI, Knudson CM, Leykin L, Korsmeyer SJ, Tilly JL. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med 1997, 3:1228-1232. 10.1038/nm1197-1228, 9359697.
10. Marcello MF, Nuciforo G, Romeo R, Di Dino G, Russo I, Russo A, Palumbo G, Schilirò G. Structural and ultrastructural study of the ovary in childhood leukemia after successful treatment. Cancer 1990, 66:2099-2104. 10.1002/1097-0142(19901115)66:10<2099::AID-CNCR2820661010>3.0.CO;2-3, 2224764.
11. Meirow D, Dor J, Kaufman B, Shrim A, Rabinovici J, Schiff E, Raanani H, Levron J, Fridman E. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod 2007, 22:1626-1633. 10.1093/humrep/dem027, 17324957.
12. Meirow D, Lewis H, Nugent D, Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod 1999, 14:1903-1907. 10.1093/humrep/14.7.1903, 10402415.
13. Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 2005, 11:69-89.
14. Ataya K, Pydyn E, Young J, Struck R. The uptake and metabolism of cyclophosphamide by the ovary. Sel Cancer Ther 1990, 6:83-92. 10.1089/sct.1990.6.83, 2367754.
15. Ramahi-Ataya AJ, Ataya KM, Subramanian MG, Struck RF. The effect of " activated" cyclophosphamide on rat granulosa cells in vitro. Reprod Toxicol 1988, 2:99-103. 10.1016/0890-6238(88)90004-4, 2980412.
16. Detti L, Uhlmann RA, Lu M, Diamond MP, Saed GM, Fletcher NM, Zhang J, Williams LJ. Serum markers of ovarian reserve and ovarian histology in adult mice treated with cyclophosphamide in pre-pubertal age. J Assist Reprod Genet 2013, 30:1421-1429. 10.1007/s10815-013-0087-x, 24057193.
17. Himelstein-Braw R, Peters H, Faber M. Morphological study of the ovaries of leukaemic children. Br J Cancer 1978, 38:82-87. 10.1038/bjc.1978.166, 2009696, 687521.
18. Oktay K, Oktem O. Regeneration of oocytes after chemotherapy: connecting the evidence from mouse to human. J Clin Oncol 2007, 25:3185-3187. 10.1200/JCO.2007.11.5097, 17664463.
19. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007, 110:2222-2229. 10.1002/cncr.23071, 17932880.
20. Sullivan SD, Castrillon DH. Insights into primary ovarian insufficiency through genetically engineered mouse models. Semin Reprod Med 2011, 29:283-298. 10.1055/s-0031-1280914, 21972066.
21. Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S, Wolf I, Kanety H, Sredni B, Meirow D. Cyclophosphamide triggers follicle activation and " burnout" ; AS101 prevents follicle loss and preserves fertility. Sci Transl Med 2013, 5:185ra62. 10.1126/scitranslmed.3005402, 23677591.
22. Desmeules P, Devine PJ. Characterizing the ovotoxicity of cyclophosphamide metabolites on cultured mouse ovaries. Toxicol Sci 2006, 90:500-509.
23. Roti Roti EC, Leisman SK, Abbott DH, Salih SM. Acute doxorubicin insult in the mouse ovary is cell- and follicle-type dependent. PLoS One 2012, 7:e42293. 10.1371/journal.pone.0042293, 3410926, 22876313.
24. Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online 2010, 20:280-285. 10.1016/j.rbmo.2009.11.010, 20113967.
25. Anderson RA, Cameron DA. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011, 96:1336-1343. 10.1210/jc.2010-2582, 21325458.
26. Anderson RA, Rosendahl M, Kelsey TW, Cameron DA. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 2013, 49:3404-3411. 10.1016/j.ejca.2013.07.014, 3807650, 23968732.
27. Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, Lyons P, Behera M, Copland S, Kimmick G, Shaw H, Snyder S, Antenos M, Woodruff T, Blackwell K. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 2008, 26:286-295. 10.1080/07357900701829777, 2883164, 18317970.
28. Anderson RA, Themmen APN, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006, 21:2583-2592. 10.1093/humrep/del201, 16820385.
29. Yu B, Douglas N, Ferin MJ, Nakhuda GS, Crew K, Lobo RA, Hershman DL. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 2010, 116:2099-2105. 3625425, 20187091.
30. La Marca A, De Leo V, Giulini S, Orvieto R, Malmusi S, Giannella L, Volpe A. Anti-Mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause. J Soc Gynecol Investig 2005, 12:545-548. 10.1016/j.jsgi.2005.06.001, 16046154.
31. Weenen C, Laven JSE, Von Bergh ARM, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BCJM, Themmen APN. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004, 10:77-83. 10.1093/molehr/gah015, 14742691.
32. La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS. Anti-Mullerian hormone (AMH): what do we still need to know?. Hum Reprod 2009, 24:2264-2275. 10.1093/humrep/dep210, 19520713.
33. De Vet A, Laven JSE, de Jong FH, Themmen APN, Fauser BCJM. Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002, 77:357-362. 10.1016/S0015-0282(01)02993-4, 11821097.
34. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010, 16:113-130. 10.1093/humupd/dmp036, 19793843.
35. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, Hasegawa Y, Noto RA, Schoenfeld D, MacLaughlin DT. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996, 81:571-576.
36. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WHB. A validated model of serum anti-müllerian hormone from conception to menopause. PLoS One 2011, 6:e22024. 10.1371/journal.pone.0022024, 3137624, 21789206.
37. Charleston JS, Hansen KR, Thyer AC, Charleston LB, Gougeon A, Siebert JR, Soules MR, Klein NA. Estimating human ovarian non-growing follicle number: the application of modern stereology techniques to an old problem. Hum Reprod 2007, 22:2103-2110. 10.1093/humrep/dem137, 17548367.
38. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril 2011, 95:170-175. 10.1016/j.fertnstert.2010.04.006, 20522327.
39. Kelsey TW, Anderson RA, Wright P, Nelson SM, Wallace WHB. Data-driven assessment of the human ovarian reserve. Mol Hum Reprod 2012, 18:79-87. 10.1093/molehr/gar059, 21933846.
40. Kevenaar ME, Meerasahib MF, Kramer P, van de Lang-Born BMN, de Jong FH, Groome NP, Themmen APN, Visser JA. Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology 2006, 147:3228-3234. 10.1210/en.2005-1588, 16556768.
41. Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca A. Anti-Müllerian hormone: clairvoyance or crystal clear?. Hum Reprod 2012, 27:631-636. 10.1093/humrep/der446, 22238112.
42. Cook CL, Siow Y, Taylor S, Fallat ME. Serum müllerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril 2000, 73:859-861. 10.1016/S0015-0282(99)00639-1, 10731554.
43. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 2006, 21:3103-3107. 10.1093/humrep/del291, 16923748.
44. Mohamed KA, Davies WAR, Lashen H. Antimüllerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertil Steril 2006, 86:1515-1517. 10.1016/j.fertnstert.2006.03.047, 16978621.
45. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril 2008, 90:395-400. 10.1016/j.fertnstert.2007.06.023, 17919608.
46. Lutchman Singh K, Muttukrishna S, Stein RC, McGarrigle HH, Patel A, Parikh B, Groome NP, Davies MC, Chatterjee R. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 2007, 96:1808-1816. 10.1038/sj.bjc.6603814, 2359977, 17533402.
47. Aslam MF, Merhi ZO, Ahmed S, Kuzbari O, Seifer DB, Minkoff H. Changes in plasma müllerian-inhibiting substance and brain-derived neurotrophic factor after chemotherapy in premenopausal women. Fertil Steril 2011, 95:1790-1793. 10.1016/j.fertnstert.2010.10.033, 3047594, 21075370.
48. Lawrenz B, Fehm T, von Wolff M, Soekler M, Huebner S, Henes J, Henes M. Centers of FertiPROTEKT Network: reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma-evaluation by using antimüllerian hormone and retrieved oocytes. Fertil Steril 2012, 98:141-144. 10.1016/j.fertnstert.2012.04.021, 22607891.
49. Lie Fong S, Lugtenburg PJ, Schipper I, Themmen APN, de Jong FH, Sonneveld P, Laven JSE. Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod 2008, 23:674-678. 10.1093/humrep/dem392, 18216040.
50. Shekarriz M, Tolentino MV, Ayzman I, Lee JC, Thomas AJ, Agarwal A. Cryopreservation and semen quality in patients with Hodgkin's disease. Cancer 1995, 75:2732-2736. 10.1002/1097-0142(19950601)75:11<2732::AID-CNCR2820751116>3.0.CO;2-S, 7743478.
51. Henry NL, Xia R, Schott AF, McConnell D, Banerjee M, Hayes DF. Prediction of Post-Chemotherapy Ovarian Function Using Markers of Ovarian Reserve. Oncologist 2013, 19(1):68-74. theoncologist.2013-0145.
52. Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE, Gosiengfiao Y, Gracia CR. Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril 2013, 99:477-483. 10.1016/j.fertnstert.2012.09.039, 3661215, 23084267.
53. Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, Løssl K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril 2010, 94:156-166. 10.1016/j.fertnstert.2009.02.043, 19342041.
54. Brougham MFH, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WHB. Anti-mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab 2012, 97:2059-2067. 10.1210/jc.2011-3180, 22472563.
55. Mörse H, Elfving M, Lindgren A, Wölner-Hanssen P, Andersen CY, Øra I. Acute onset of ovarian dysfunction in young females after start of cancer treatment. Pediatr Blood Cancer 2013, 60:676-681. 10.1002/pbc.24327, 23015461.
56. Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer 2012, 118:1933-1939. 10.1002/cncr.26403, 3220922, 21850728.
57. Gracia CR, Sammel MD, Freeman E, Prewitt M, Carlson C, Ray A, Vance A, Ginsberg JP. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012, 97:134-140. 10.1016/j.fertnstert.2011.10.040, 22137491.
58. Hagen CP, Vestergaard S, Juul A, Skakkebæk NE, Andersson A-M, Main KM, Hjøllund NH, Ernst E, Bonde JP, Anderson RA, Jensen TK. Low concentration of circulating antimüllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. Fertil Steril 2012, 98:1602-1608. 10.1016/j.fertnstert.2012.08.008, 22959460.
59. Steiner AZ, Herring AH, Kesner JS, Meadows JW, Stanczyk FZ, Hoberman S, Baird DD. Antimüllerian hormone as a predictor of natural fecundability in women aged 30-42 years. Obstet Gynecol 2011, 117:798-804. 10.1097/AOG.0b013e3182116bc8, 3825553, 21422850.
60. van Dorp W, van den Heuvel-Eibrink MM, de Vries AC, Pluijm SM, Visser JA, Pieters R, Laven JS. Decreased serum anti-Müllerian hormone levels in girls with newly diagnosed cancer. Hum Reprod 2014, 29:337-342. 10.1093/humrep/det442, 24345579.